• BioAtla reported fiscal 2025 net loss of $60 million, narrowing from $70 million a year earlier.
• Revenue fell 81.82% to $2 million.
• Operating loss narrowed to $59 million as total operating expenses dropped to $61 million.
• Cash and cash equivalents totaled about $7 million at Dec. 31, 2025, raising substantial doubt about its ability to continue as a going concern.
• Board initiated a formal strategic review to maximize shareholder value, evaluating options including asset sales, licensing, partnerships, or other corporate transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioAtla Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-134499), on March 31, 2026, and is solely responsible for the information contained therein.